M2care and Inserm Transfert announce the signing of a strategic alliance aimed at supporting the development of medical technologies and the creation of innovative start-ups in the healthtech field
Paris, Lyon, December 10, 2024 – M2care, a venture studio specializing in the creation and development of companies in the field of medical devices, diagnostics, and digital health, and Inserm Transfert, the private valorization subsidiary of Inserm, specializing in innovation and technology transfer in life sciences, are joining forces to support the emergence of innovations from Inserm laboratories to bring them to market, benefiting patients and public health.
In a context where innovation is the driving force behind technical and medical progress, M2care and Inserm Transfert will combine their expertise to accelerate the development of deeptech start-ups that leverage academic research. This strategic partnership resonates with the excellence of the research conducted at Inserm and Inserm Transfert’s expertise in early detection, innovation maturation, and business creation support, as well as M2care’s entrepreneurial know-how in the medical technology sector.
Thus, innovative projects detected by Inserm Transfert teams from Inserm researchers will be thoroughly analysed and evaluated by M2care in their scientific, clinical, regulatory, industrial, and market dimensions, relying on its teams and experts from its vast ecosystem. M2care’s ambition is to create start-ups jointly with project leaders, with initial funding provided by the venture studio’s investment fund. This financial, strategic, and operational support increases the likelihood that these innovations will reach their markets for the benefit of patients.
This strategic partnership will also be realized through the involvement of the M2care team in the entrepreneurship support program established by Inserm Transfert since 2017. This program provides personalized support to researchers on all aspects of creating a healthtech start-up to help them structure their project and become “enlightened founders” capable of leading a deeptech business project in human health. Nearly 150 business creation projects have been supported through this program since its inception.
A mutual commitment for a lasting impact.
Florence Thueux, President of M2care, declares: “M2care is committed to thoroughly examining projects from Inserm Transfert’s portfolio, perfectly aligned with our investment philosophy. This partnership strengthens our ability to conduct preliminary analyses on valorization strategies and enrich our project pipeline with high-quality projects while sharing best practices in the field”.
For Pascale Augé, President of the Executive Board of Inserm Transfert: “The alliance between M2care and Inserm Transfert is a guarantee of success, combining the scientific excellence of Inserm researchers, Inserm Transfert’s valorization expertise, and M2care’s entrepreneurial know-how. We bring a complementary, global, and strategic vision essential to the realization and valorization of the most ambitious projects. Together, we are preparing the future of medical technologies, propelling today’s discoveries into tomorrow’s clinical innovations”.
About Inserm Transfert
Inserm Transfert, a private subsidiary of Inserm, is responsible for the valorization and innovations of Inserm and its academic partners in human health and promotes long-term technology transfers according to international best practices. Founded in 2000, Inserm Transfert manages the entire value chain of innovation and the transfer of knowledge from Inserm research laboratories to the industrial world, from invention disclosure to industrial partnership and business creation. Inserm Transfert also offers its services in the assembly and management of national, European, and international projects, as well as support for the valorization of clinical research and health data/databases and cohorts.
About M2care:
M2care is a European venture studio created at the initiative of Mérieux Développement and specialized in the HealthTech field. M2care’s key shareholders include Institut Mérieux and CEA Investissement. M2care founds, develops, and finances innovative projects at early stages of maturity, alongside project leaders. M2care is an essential link between academics, investors, and industry, thanks to its investment and operational deployment capacity. With an experienced and complementary team of entrepreneurs in residence, a unique international network, and ad hoc ecosystems built for each project, M2care enables ideas and technologies born in laboratories to become health products brought to market, serving public health improvement and benefiting patients.
Press contacts:
Agence Acorelis – Gilles Petitot – 06 20 27 65 94 – gilles.petitot@acorelis.com
Inserm Transfert – Ingrid Hargot – 06 09 40 41 63 – communication@inserm-transfert.fr
M2care – Renaud Confavreux – 06 11 67 19 77 – renaud.confavreux@m2.care
